Parandalimi i nekrozës së mandibulës dhe/ose maksilës gjatë terapisë me bifosfonate në pacientët me osteoporozë
DOI:
https://doi.org/10.55312/op.vi1.4607Abstract
Pavarësisht riskut për të zhvilluar nekrozën mandibulare dhe/ose maksilare gjatë përdorimit të bifosfonateve në osteoporozë, ekzistojnë mënyra parandalimi që kërkojnë bashkëpunimin e mjekut reumatolog, pacientit dhe mjekut stomatolog.Keywords:
bifosfonatet, osteoporoza, nekroza mandibulare dhe/ose maksilare.Downloads
References
-
Jacqueline L. Longe, The Gale encyclopaedia of medicine, third edition, volume 4, 2006, 2714- 2718.
-
Philip Seo, Alan Hakim, Gavin Clunie, Inam Haq, Oxford American Handbook of Rheumatology, second edition, 2013, 444-453.
-
Argjend Tafaj, Reumatologjia, Albpaper, 2004, 321-332.
-
G. Birdwood, Understanding osteoporosis and its treatment, The Parthenon Publishing Group Ltd, 1996, 17-36.
-
Skënder Durrësi, Formular Terapeutik, Mediaprint, 2010, 320-322.
-
John H. Klippel, Primer on the rheumatic diseases, thirteenth edition, Arthritis foundation, 2008, 576-598
-
Lars Rassmuson, Jahan Abtahi, Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors and treatment, International Journal of Dentistry, volume 2014, 1-9
-
M. Doherty, Therapeutic Strategies in Rheumatology, Atlas Medical Publishing Ltd 2010, 179-194.
-
NSw, Department of Health Guidelines, Prevention of osteonecrosis of the jaw in patients on bisphosphonate therapies, Centre for oral health strategy, 2012, 1-31.
-
Compston, J, Cooper, A, Cooper, C et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporosis. 2017; 12: 43.
-
Adler, RA, El-Hajj Fuleihan, G, Bauer, DC et al. Managing osteoporosis in patients on longterm bisphosphonate treatment: report of a
-
Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016; 31: 16–35.
-
Laius, O.; Pisarev, H.; Maasalu, K.; Kõks, S.; Märtson, A. Adherence to osteoporosis medicines in Estonia, A comprehensive 15-year retrospective prescriptions database study. Arch. Osteoporosis. 2017, 12, 19.
References
Jacqueline L. Longe, The Gale encyclopaedia of medicine, third edition, volume 4, 2006, 2714- 2718.
Philip Seo, Alan Hakim, Gavin Clunie, Inam Haq, Oxford American Handbook of Rheumatology, second edition, 2013, 444-453.
Argjend Tafaj, Reumatologjia, Albpaper, 2004, 321-332.
G. Birdwood, Understanding osteoporosis and its treatment, The Parthenon Publishing Group Ltd, 1996, 17-36.
Skënder Durrësi, Formular Terapeutik, Mediaprint, 2010, 320-322.
John H. Klippel, Primer on the rheumatic diseases, thirteenth edition, Arthritis foundation, 2008, 576-598
Lars Rassmuson, Jahan Abtahi, Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors and treatment, International Journal of Dentistry, volume 2014, 1-9
M. Doherty, Therapeutic Strategies in Rheumatology, Atlas Medical Publishing Ltd 2010, 179-194.
NSw, Department of Health Guidelines, Prevention of osteonecrosis of the jaw in patients on bisphosphonate therapies, Centre for oral health strategy, 2012, 1-31.
Compston, J, Cooper, A, Cooper, C et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporosis. 2017; 12: 43.
Adler, RA, El-Hajj Fuleihan, G, Bauer, DC et al. Managing osteoporosis in patients on longterm bisphosphonate treatment: report of a
Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016; 31: 16–35.
Laius, O.; Pisarev, H.; Maasalu, K.; Kõks, S.; Märtson, A. Adherence to osteoporosis medicines in Estonia, A comprehensive 15-year retrospective prescriptions database study. Arch. Osteoporosis. 2017, 12, 19.
Shqip
English
Italiano
